Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CLDI

Calidi Biotherapeutics Inc

Apr 15 • 04:00PM ET

0.6000

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.03	Insider Own	42.13%	Shs Outstand	35.52M	Perf Week	57.89%
Market Cap	21.31M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	0.00%	Shs Float	20.56M	Perf Month	-1.48%
Income	-16.75M	PEG	-	EPS next Q	-0.28	Inst Own	5.71%	Short Float	0.72%	Perf Quarter	-53.49%
Sales	0.00M	P/S	-	EPS this Y	45.66%	Inst Trans	-86.27%	Short Ratio	0.36	Perf Half Y	-80.36%
Book/sh	-0.23	P/B	-	EPS next Y	32.98%	ROA	-63.34%	Short Interest	0.15M	Perf Year	-94.12%
Cash/sh	0.06	P/C	10.40	EPS next 5Y	-	ROE	-115.44%	52W Range	0.38 - 13.79	Perf YTD	-60.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-95.65%	Beta	0.17
Dividend TTM	-	Quick Ratio	0.42	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	57.89%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	0.42	EPS Y/Y TTM	-2064.71%	Oper. Margin	0.00%	RSI (14)	49.84	Volatility	56.27% 24.01%
Employees	41	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	3.25
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	11.53%	Payout	-	Rel Volume	0.00	Prev Close	0.60
Sales Surprise	-	EPS Surprise	-12.20%	Sales Q/Q	-	Earnings	Mar 15 AMC	Avg Volume	410.08K	Price	0.60
SMA20	6.97%	SMA50	-6.31%	SMA200	-84.19%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-23	Initiated	H.C. Wainwright	Buy	$11
Oct-09-23	Initiated	Robert W. Baird	Outperform	$9

Today 08:31AM	Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering (Business Wire)
Apr-09-24 07:00AM	Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Companys Novel Immunotherapies at the AACR Annual Meeting 2024 (Business Wire) +62.39%
Mar-15-24 04:05PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results (Business Wire)
Mar-11-24 07:00AM	Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer (Business Wire)
Feb-12-24 07:00AM	Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference (Business Wire)
07:00AM	Loading…
Jan-08-24 07:00AM	Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board (Business Wire) +6.84%
Dec-13-23 07:00AM	Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit (Business Wire)
Dec-12-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors (Business Wire)
Nov-20-23 07:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones (Business Wire)
Nov-14-23 04:05PM	Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results (Business Wire) -6.98%
Nov-03-23 07:00AM	Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancers 38th Annual Meeting (SITC 2023) (Business Wire) +18.90%
Nov-01-23 07:00AM	Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment (Business Wire) -10.55%
Oct-30-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer (Business Wire) -13.19%
Oct-10-23 07:00AM	Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023 (Business Wire)
Sep-13-23 05:50AM	Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies (GlobeNewswire) -38.75%
04:05PM	Loading…
Sep-11-23 04:05PM	First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments (GlobeNewswire)
Aug-24-23 12:06PM	FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET (GlobeNewswire)
Aug-22-23 11:41AM	FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET (GlobeNewswire) -10.85%
Aug-16-23 06:00AM	Flag Stockholders: Reminder to Vote for Proposed Business Combination (GlobeNewswire)
Aug-07-23 05:00AM	First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination (GlobeNewswire)
Jun-23-23 05:00AM	Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer (GlobeNewswire)

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDI

Calidi Biotherapeutics Inc

Upgrade your FINVIZ experience